EUVIMEDEUVIMED entdecken
Open Access

Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease

Keith A Josephs iD, Nirubol Tosakulwong iD, Stephen D Weigand, Jonathan Graff-Radford, Christopher G Schwarz iD, Matthew L Senjem iD, Mary M Machulda iD, Kejal Kantarci iD, David S Knopman iD, Aivi Nguyen iD, R Ross Reichard, Dennis W Dickson iD und 4 weitere

Science Translational Medicine · 24.07.2024 · 16 (757)

DOI: 10.1126/scitranslmed.ado8076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 24.07.2024. Verfasst von Keith A Josephs und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Alzheimer Disease, tau Proteins, Carbolines. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIDCD NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[ 18 F]-Flortaucipir positron emission tomography (PET) is considered a good biomarker of Alzheimer’s disease. However, it is unknown how flortaucipir is associated with the distribution of tau across brain regions and how these associations are influenced by amyloid-β. It is also unclear whether flortaucipir can detect tau in definite primary age–related tauopathy (PART). We identified 248 individuals at Mayo Clinic who had undergone [ 18 F]-flortaucipir PET during life, had died, and had undergone an autopsy, 239 cases of which also had amyloid-β PET. We assessed nonlinear relationships between flortaucipir uptake in nine medial temporal and cortical regions, Braak tau stage, and Thal amyloid-β phase using generalized additive models. We found that flortaucipir uptake was greater with increasing tau stage in all regions. Increased uptake at low tau stages in medial temporal regions was only observed in cases with a high amyloid-β phase. Flortaucipir uptake linearly increased with the amyloid-β phase in medial temporal and cortical regions. The highest flortaucipir uptake occurred with high Alzheimer’s disease neuropathologic change (ADNC) scores, followed by low-intermediate ADNC scores, then PART, with the entorhinal cortex providing the best differentiation between groups. Flortaucipir PET had limited ability to detect PART, and imaging-defined PART did not correspond with pathologically defined PART. In summary, spatial patterns of flortaucipir mirrored the histopathological tau distribution, were influenced by the amyloid-β phase, and were useful for distinguishing different ADNC scores and PART.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyAlzheimer Diseasetau ProteinsCarbolinesAmyloid beta-PeptidesTauopathiesHumansAgedFemaleMaleAged, 80 and overMiddle AgedBrain

Substanzen

tau ProteinsCarbolinesAmyloid beta-Peptides7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Information Technology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Keith A Josephs, Nirubol Tosakulwong, Christopher G Schwarz, Matthew L Senjem, Mary M Machulda, Kejal Kantarci, David S Knopman, Aivi Nguyen, Dennis W Dickson, Ronald C Petersen, Clifford R Jack

Förderung

  • NINDS NIH HHS
  • NIDCD NIH HHS
  • NIA NIH HHS

Zitieren

APA

Josephs, K. A., Tosakulwong, N., Weigand, S. D., Graff-Radford, J., Schwarz, C. G., Senjem, M. L., Machulda, M. M., Kantarci, K., Knopman, D. S., Nguyen, A., Reichard, R. R., Dickson, D. W., Petersen, R. C., Lowe, V. J., Jack, C. R., & Whitwell, J. L. (2024). Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease. Science Translational Medicine, 16(757). https://doi.org/10.1126/scitranslmed.ado8076

Vancouver

Josephs KA, Tosakulwong N, Weigand SD, Graff-Radford J, Schwarz CG, Senjem ML, et al. Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease. Science Translational Medicine. 2024;16(757). doi:10.1126/scitranslmed.ado8076

BibTeX
@article{Josephs2024,
  author = {Josephs, Keith A and Tosakulwong, Nirubol and Weigand, Stephen D and Graff-Radford, Jonathan and Schwarz, Christopher G and Senjem, Matthew L and Machulda, Mary M and Kantarci, Kejal and Knopman, David S and Nguyen, Aivi and Reichard, R Ross and Dickson, Dennis W and Petersen, Ronald C and Lowe, Val J and Jack, Clifford R and Whitwell, Jennifer L},
  title = {Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {757},
  doi = {10.1126/scitranslmed.ado8076}
}
Kostenlos starten →